Endocrinologic and Metabolic Drugs Advisory Committee
Committee Meeting on May 10th from 8:00 a.m. to 5:00 p.m.
Agenda: The committee will discuss the safety and efficacy of new drug application (NDA) 22–529 (lorcaserin hydrochloride) tablets, manufactured by Arena Pharmaceuticals, Inc., as an adjunct to diet and exercise for weight management in patients with a body mass index (BMI) equal to or greater than 30 kilograms (kg) per square meter or a BMI equal to or greater than 27 kg per square meter if accompanied by weight-related comorbidities.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment